BrainChip ‘s AI processor is powering NaNose (Nano Artificial Nose) which tests exhaled breath samples for COVID-19.
Using the NaNose Medical sensor array to collect the data, and Akida to perform the diagnosis, can have a higher rate of reliability than current testing methods and poses less risk to medical professionals because no saliva or mucus samples are collected.
COVID-19 is known to be spread through respiratory droplets, and more recently has been confirmed to be airborne.
Because Akida’s “Edge AI” is a complete neural processor that does not require an external CPU, memory, or Deep Learning Accelerator (DLA), and because it is ultra-low power, it offers a realistic opportunity for an inexpensive hand-held diagnostic testing tool akin to a breathalyzer.
AI/ML is transformational in medical and healthcare, from bioscience research and pathology to primary care. Akida neuromorphic computing and advanced neural networking processors support new and evolving uses such as identifying disease markers in blood or breath, detecting abnormalities in X-rays, CT scans, and MRIs, cancer diagnostics, device/sensor data, and more.
Akida brings artificial intelligence to the edge in a way that existing technologies are not capable of. The solution is high-performance, small, ultra-low power and enables a wide array of edge capabilities.
The Akida Neuromorphic System-on-Chip, licensable IP, and Akida Development Environment machine learning framework are targeted for applications and devices including Smart Home, Smart City, Smart Healthcare and Smart Transportation.
Source: electronicsweekly
